Aegerion Pharmaceuticals Announces Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Aegerion Pharma (AEGR) Misses Q2 EPS by 9c, Sales Beat; Reiterates FY Sales View
August 5, 2015 4:40 PM EDTAegerion Pharma (NASDAQ: AEGR) reported Q2 EPS of ($0.37), $0.09 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $64.2 million versus the consensus estimate of $58.98 million.
Company reiterates 2015 total net product sales guidance of between $205 and $235 million
Chief Executive Officer Sandford D. Smith commented,... More
